MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.399
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Incidence, Risk Factors, and Impact on Survival of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology
Cancer ResearchOncology
2019English

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Association Between Adverse Events and Quality of Life in Patients Treated With Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Chemoradiotherapy Followed by Durvalumab in Patients With Unresectable Advanced Non‐small Cell Lung Cancer: Management of Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Nivolumab Improves Survival for Patients With Advanced Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Predictive Factors Associated With Prolonged Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Gefitinib

British Journal of Cancer
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy